To the content
3 . 2022

The path of patients with hyperprolactinemia in real clinical practice (clinical cases)


One of the most common endocrine disorders is hyperprolactinemia syndrome, which occurs due to the presence of a prolactin-secreting pituitary tumor. Excess production of prolactin, the volume and growth characteristics of macroprolactinomas cause a variety of clinical manifestations and, as a result, initial appeal of patients to doctors of related specialties. Timely diagnosis and treatment of this condition significantly affect the functioning of the reproductive system, and also prevent complications caused by long-term hyperprolactinemia. And this generally contributes to maintaining the patient’s quality of life. Despite more than 30 years of experience in prescribing cabergoline, some aspects of its therapeutic use remain to be elucidated. Therefore, discussion of the tactics of managing patients with hyperprolactinemia is still relevant today.

In the article, on the example of 3 patients (2 women and 1 man), characteristic clinical manifestations of hyperprolactinemia syndrome, features of disease course, as well as value of timely diagnosis and effectiveness of therapy with dopamine agonists are considered.

Keywords:hyperprolactinemia; prolactinoma; cabergoline

Funding. The study had no sponsor support.

Conflict of interest. The authors declare no conflict of interest.

For citation: Ilovaiskaya I.A., Ukhanova Yu.A., Metlushko E.D. The path of patients with hyperprolactinemia in real clinical practice (clinical cases). Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2022; 11 (3): 80–8. DOI: (in Russian)


1. Frisch R.E., Revelle R. Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science. 1970; 169 (3943): 397–9. DOI: PMID: 5450378

2. Dedov I.I., Melnichenko G.A., Dzeranova L.K., Andreeva E.N., et al. Russian association of endocrinologists national practice guidelines (clinical signs, diagnosis, differential diagnosis, treatment). Hyperprolactinemia. (Project)

3. Colao A., Di Sarno A., Guerra E., De Leo M., et al. Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. Nat Clin Pract Endocrinol Metab. 2006; 2 (4): 200–10. DOI:

4. Adamyan L.V., Iarmolinskaia M.I., Suslova E.V. Hyperprolactinemia syndrome: from theory to practice. Problemy Reproduktsii [Russian Journal of Human Reproduction]. 2020; 26 (2): 27‑33. DOI: (in Russian)

5. Dabbous Z., Atkin S.L. Hyperprolactinaemia in male infertility: Clinical case scenarios. Arab J Urol. 2017; 16 (1): 44‑52. DOI:

6. Sengupta P., Dutta S., Karkada I.R., Chinni S.V. Endocrinopathies and Male Infertility. Life (Basel). 2021; 12 (1): 10. DOI:

7. Fachi M.M., de Deus Bueno L., de Oliveira D.C., da Silva L.L., Bonetti A.F. Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta-analysis. J Clin Pharm Ther. 2021; 46 (6): 1549–56. DOI:

8. Melnichenko G.A., Dzeranova L.K., Pigarova E.A., Vorotnikova S.Yu., Tarasova T.S. The data of national medical interview on hyperprolactinemia treatment in real clinical practice. Ozhirenie i metabolizm [Obesity and Metabolism]. 2016; 13 (2): 14–9. DOI: (in Russian)

9. Dzeranova L.K., Vorotnikova S.Yu. Cabergoline: 30-year unity of experience and confidence. Rossiyskii Vestnik Akushera-Ginekologa [Russian Bulletin of Obstetrician-Gynecologist]. 2013; 13 (6): 45‑9. (in Russian)

10. Dzeranova L., Skuridina D., Vorotnicova S., Pigarova E. The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline. Ozhirenie i metabolizm [Obesity and Metabolism]. 2016; 13 (3): 60–3. DOI: (in Russian)

11. Glezer A., Bronstein M.D. Prolactinomas, cabergoline, and pregnancy. Endocrine. 2014; 47 (1): 64–9. DOI:

12. Auriemma R.S., Perone Y., Di Sarno A., Grasso L.F., et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab. 2013; 98 (1): 372–9. DOI: PMID: 23162092.

13. O’Sullivan SM, Farrant MT, Ogilvie CM, Gunn AJ, Milsom SR. An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists. Aust N Z J Obstet Gynaecol. 2020; 60 (3): 405–11. DOI:

14. Souteiro P., Belo S., Carvalho D. Dopamine agonists in prolactinomas: when to withdraw? Pituitary. 2020; 23 (1): 38–44. DOI:

15. Dedov I.I., Melnichenko G.A., Shestakova M.V., Troshina E.A., et al. Russian national clinical recommendations for morbid obesity treatment in adults. 3rd revision (Morbid obesity treatment in adults). Ozhirenie i metabolizm [Obesity and Metabolism]. 2018; 15 (1): 53–70. DOI: (in Russian)

16. Krivosheeva Yu.G., Ilovayskaya I.A. The prevalence rate of hypopituitarism in patients with pituitary macroadenomas with various hormonal activities. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2021; 49 (4): 261–7. DOI: (in Russian)

17. Krivosheeva Yu.G., Ilovayskaya I.A. Primary signs of pituitary macroadenomas of diff erent hormonal activity and specialists to whom patients referred at the first time. Medicinskij vestnik Ûga Rossii [Medical Herald of the South of Russia]. 2022; 13 (1): 65–71. DOI: (in Russian)

18. Dedov I.I., Melnichenko G.A., Dzeranova L.K., Pigarova E.A., et al. Pituitary incidentalomas: the clinical picture, diagnostics, differential diagnostics, and methods of treatment. Problemi Endocrinologii [Problems of Endocrinology]. 2015; 61 (3): 57–68. DOI: (in Russian)

19. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., et al; Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96 (2): 273–88. DOI: PMID: 21296991.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)

Ametov Alexander S.
Honored Scientist of the Russian Federation, Doctor of Medical Sciences, Professor, Head of Subdepartment of Endocrinology, Head of the UNESCO Network Chair on the subject «Bioethics of diabetes as a global problem» of the Russian Medical Academy of Continuous Professional Education (Moscow)

Journals of «GEOTAR-Media»